News
Advertisement
Advertisement
Advertisement
Advertisement
The FDA has approved an sBLA for deflazacort that expands the label to patients aged 2 to 5 with Duchenne muscular dystrophy.
The highly specific myostatin activation inhibitor is expected to enter phase 2 study in spinal muscular atrophy, according to SRK-015’s manufacturer, Scholar Rock.
The FDA has set a PDUFA date of March 25, 2020.
The director of Behavioral Medicine at the Mellen Center for MS Treatment and Research at the Cleveland Clinic spoke about the importance of caring for patients with MS by using a team-based approach.
Zilucoplan, also being developed for generalized myasthenia gravis, is expected to enter into a phase 2 clinical trial in IMNM in the second half of 2019, according to Ra Pharma.
Are his symptoms related to a fall that occurred 2 years earlier at work?
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition
3
RELIEV-CM Pilot Study Data Further Supports ShiraTronics’ Neuromodulation Device to Treat Chronic Migraine
4
Insights Into the Neurobiology of Stuttering From 2025 STARS Conference: Shahriar SheikhBahaei, PhD
5
